Publications by authors named "Jian-Rong Peng"
Article Synopsis
- The study investigates the cardiovascular risks associated with Immune Checkpoint Inhibitors (ICIs) compared to other cancer therapies, analyzing data from over 188,000 cancer patients in Taiwan.
- It found no significant increase in major cardiovascular events, such as cardiac death and heart failure, among patients treated with ICIs.
- Notably, ICI patients experienced a lower risk of non-fatal stroke, particularly benefiting those with diabetes, suggesting that ICIs may have protective cardiovascular effects that warrant further research.
Background: While ivabradine has demonstrated benefits in heart rate control and prognosis for chronic heart failure patients, its application in acute decompensated heart failure remains underexplored.
Hypothesis: For patients with acute decompensated heart failure with reduced ejection fraction (HFrEF) who are intolerant to β-blockers or unable to further titrate their dosage, the use of ivabradine is hypothesized to be effective and safe is improving outcomes.
Methods: This retrospective, multicenter database analysis included patients with hospitalized decompensated heart failure with a left ventricular ejection fraction of ≤40% from June 1, 2015 to December 31, 2020.
An elevated heart rate is an independent risk factor for cardiovascular disease; however, the relationship between heart rate control and the long-term outcomes of patients with heart failure with reduced ejection fraction (HFrEF) remains unclear. This study explored the long-term prognostic importance of heart rate control in patients hospitalized with HFrEF. : We retrieved the records of patients admitted for decompensated heart failure with a left ventricular ejection fraction (LVEF) of ≤40%, from 1 January 2005 to 31 December 2019.
View Article and Find Full Text PDFArticle Synopsis
- Patients with type 2 diabetes (T2D) undergoing percutaneous coronary intervention (PCI) face higher risks of cardiovascular and renal issues, and this study compares outcomes between those treated with sodium-glucose cotransporter-2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitors (DPP4i).
- A nationwide study analyzed data from over 41,000 patients, finding that SGLT2i showed lower risks for heart failure hospitalization, coronary revascularization, kidney issues, and all-cause mortality compared to DPP4i.
- The results suggest that SGLT2i is more beneficial for T2D patients after PCI, and further research is
Background: Patients with chronic kidney disease (CKD) and coronary instent restenosis (ISR) treated with drug-coated balloon (DCB) angioplasty have been excluded from randomized controlled trials. We aimed to investigate the clinical impact of CKD stratified by severity, on clinical outcomes for patients with ISR treated with DCB angioplasty.
Methods: This cohort study enrolled 1,376 patients treated with DCB angioplasty; 639 CKD patients defined as having an estimated glomerular filtration rate (eGFR) <60 mL/min/1.
Background: The use of electronic health (e-health) resources is emerging as an alternative method to improve the secondary prevention of coronary artery disease (CAD). The aim of this study was to describe the influence of an e-health application in holistic healthcare for patients with CAD.
Methods: A quasiexperiment with nonequivalent groups design recruited outpatients with a high risk of CAD admitted for cardiac catheterization.
Background And Objectives: The aim of this study was to identify clinical, lesional, and procedural predictors for adverse outcomes of coronary angioplasty and stenting in coronary bypass candidates.
Subjects And Methods: This cohort study included 107 consecutive candidates for coronary artery bypass surgery who underwent percutaneous coronary intervention with multiple coronary stents between Jan 2004 and Dec 2011. The study endpoint was major adverse cardiovascular events (MACEs) including all-cause mortality, nonfatal myocardial infarction, repeat revascularization, and stent thrombosis.